Performance Medical Technologies (PMT) is committed to supporting physicians on the front lines of neurodegenerative care. Our mission is to deliver clinically validated, regulatory-approved clinical therapeutics designed to slow the progression of early-stage Parkinson’s Disease and other neurodegenerative conditions—grounded in science, supported by data, and ready for practice.
PMT offers a comprehensive clinical platform for providers:
We are pursuing new clinical indications for a biologic targeting mitochondrial dysfunction and neuroinflammation, two key drivers of PD and related conditions. Regulatory submissions are being pursued with both the FDA and EMA.
Our HIPAA- and GDPR-compliant platform enables real-time clinical data capture, patient-reported outcomes tracking, and evidence-based treatment optimization.
PMT will offer onboarding, training, and support to ensure providers can confidently implement the therapy as part of their neurodegenerative care protocols.
By partnering with PMT, you’ll gain access to a network of researchers, clinicians, and early adopters working to transform the standard of care for neurodegenerative diseases.
Join us in leading a new era of neurotherapeutics—where early diagnosis, targeted biologics, and data-informed care reshape what’s possible for millions of patients.
PMT is committed to supporting healthcare providers with secure data access, high-quality products, and specialized training to ensure optimal treatment outcomes.
